Information Provided By:
Fly News Breaks for May 24, 2016
UTHR
May 24, 2016 | 07:19 EDT
Argus analsyt Jacob Kilstein downgraded United Therapeutics to Hold to reflect declining revenue for key products Remodulin and Tyvaso, delayed FDA approval of a new implantable pump for Remodulin, and the unexpected resignation of two senior executives on the day of the earnings release. Given the current challenges, the analyst views shares as fairly valued and would need to see a clear strategy for overcoming the declining sales of Remodulin and Tyvaso and countering the competitive pressure on Orenitram before becoming more constructive on United Therapeutics shares.
News For UTHR From the Last 2 Days
There are no results for your query UTHR